You already know. You can look at a calendar and tell someone which week the groin will start. Four or five days before bleeding the ache begins, then the tightness, then the nodule, and by the time you are actually menstruating it is a full flare. Then it settles. You get a fortnight of something resembling normality. Then it begins again.
If you have raised this, you may have been told it is coincidence. Or told "yes, hormones", handed a prescription, and given no explanation at all. Neither is adequate, because the cyclical pattern is not a curiosity. It is a direct read-out of the mechanism driving your disease, and it points precisely at where correction has to happen.
The pattern is real, and it is under-recognised
HS is diagnosed considerably more often in women than in men, and many women with HS report that flares cluster in the days before menstruation. Yet the cycle is frequently never asked about in a dermatology consultation, and many women never volunteer it, because it sounds anecdotal even to the person living it.
It is not anecdotal. It is periodic, reproducible, and mechanistically explainable.
What the apocrine unit is listening to
The follicular units involved in HS — axillae, groin, inframammary folds, perineum — sit in apocrine-gland-bearing territory, and that tissue is androgen-responsive. Androgen signalling influences how readily the follicular epithelium hyperkeratinises, and hyperkeratinisation is the first step of the entire cascade: occlusion, dilatation, rupture, and then a very large innate immune reaction to follicular contents spilling into the dermis.
Notice what this does not mean. It does not mean your testosterone is high. Most women with HS have serum androgens sitting comfortably in the normal range, which is exactly why hormone panels come back "fine" and the conversation ends there. What matters at the follicle is not the number on the report but the signal reaching the receptor: the free, unbound fraction of androgen, local conversion within the tissue, and how sensitive that tissue is to a given amount. Normal bloods and a strongly androgen-driven skin disease are entirely compatible.
Why the premenstrual window specifically
| Cycle window | Hormonal state | What the follicle experiences |
|---|
| Follicular phase | Oestrogen rising | Relative androgen signal at its lowest; many women describe this as their calmest skin |
| Ovulation | Oestrogen peaks, then falls | Transitional |
| Mid-luteal | Progesterone dominant | Variable; sweat and occlusion increase |
| Late luteal (premenstrual) | Oestrogen and progesterone both falling; androgen output does not fall with them | Relative androgen signal at its highest; innate immune reactivity shifts; a predictable flare window |
In the days before menstruation, oestrogen and progesterone withdraw and androgen production does not withdraw in step with them. Your absolute androgen level need not change at all for the relative androgen effect at an androgen-sensitive follicle to rise sharply. Add the shift in innate immune reactivity across the luteal phase, fluid retention, and increased friction in the folds, and the window stops looking random.
Your flare is not badly timed. It is precisely timed. That is the point.
The part that gets missed: the gut–hormone loop
This is what almost never gets explained, and it is why hormonal treatment alone does not hold.
Insulin resistance raises your active androgen fraction. Sex hormone binding globulin (SHBG) binds testosterone and keeps it inactive. Insulin resistance lowers SHBG. Lower SHBG means a higher free testosterone fraction — a stronger signal arriving at the follicle — with no change whatsoever in your total testosterone. That is how a woman with a normal hormone panel ends up with a hormonally driven skin disease.
Insulin and IGF-1 act on the follicle directly, stimulating keratinocyte proliferation and apocrine and sebaceous activity, amplifying the same occlusive process the androgen signal is already driving.
The gut decides how much oestrogen you keep. Gut bacteria produce β-glucuronidase, which deconjugates oestrogens the liver has already prepared for excretion and returns them to circulation. Dysbiosis alters that recycling, and so alters the oestrogen-to-androgen ratio your tissues actually see — the very ratio that swings premenstrually.
And barrier compromise feeds all of it. A permeable intestinal barrier admits bacterial endotoxin into circulation continuously, raising baseline innate inflammatory tone. That tone worsens insulin sensitivity, which lowers SHBG further, which raises free androgen further.
Read it as a circuit, not a list:
Gut barrier compromise → systemic inflammatory tone → insulin resistance → lower SHBG → higher free androgen at the follicle → occlusion and rupture → more inflammation → further barrier and metabolic damage.
Which is why "hormonal HS" and "gut HS" are not two diseases. They are one loop, entered at different points. It is also why HS and PCOS overlap so often: both sit squarely on insulin resistance plus androgen sensitivity.
Why the pill and spironolactone help — and why symptoms return when you stop
They help for a good reason, and it should be said plainly. Combined oral contraceptives raise SHBG and reduce ovarian androgen output. Anti-androgens such as spironolactone block the androgen receptor. Both genuinely reduce the androgen signal reaching the follicle, and for many women that means fewer flares and a quieter premenstrual week. That benefit is real and it is not to be waved away.
But look at where in the loop they act. They intervene at the output — the hormonal signal itself — and nowhere else. The intestinal barrier is unchanged. The microbiome is unchanged. The insulin resistance that lowered your SHBG in the first place is unchanged. The inflammatory tone is unchanged. The relationship that produced the hormonal pattern is left entirely intact, with a medication placed between it and your skin.
So the outcome is exactly what the mechanism predicts: benefit while the medication continues, symptoms returning when it stops. That is not the drug failing. That is the drug working, at the level it works at.
None of this is a reason to stop your medication. EPOH begins while you continue what you are taking. As internal correction takes effect, the medication is reviewed with your prescribing physician, and reduction, where appropriate, is gradual and structured — with discontinuation as the goal, not the opening move.
In EPOH's five sequential phases, hormonal work is not given a phase of its own. That is deliberate.
Phase L — Lowering the Load (4–8 weeks). Oral formulations reducing accumulated inflammatory load (Ama) and restoring digestive capacity (Agni), with immune-calming compounds. You cannot recalibrate hormonal signalling across an inflamed, leaking gut, so this comes first.
Phase I — Internal Healing (8–16 weeks). The primary correction phase: gut lining integrity, microbiome repair, immune recalibration and hormonal patterns, addressed together because they are one system rather than four. Formulations are compounded to your driver profile — here, typically hormonal balance and metabolic function leading, gut health beneath them, and stress and cortisol as the amplifier, since sustained cortisol worsens insulin resistance and competes for the same precursors as androgen production.
In Ayurvedic terms: Pitta-driven inflammation arising from Ama and Rakta Dushti, obstructing the Svedavaha Srotas, with a Vata-governed cyclical rhythm supplying both the timing and the pain.
What change actually looks like
The first thing that shifts is usually not lesion size. It is the window. The premenstrual flare arrives later, arrives milder, and resolves faster.
That is Recovery Stage 1 (Internal Shift, weeks 1–4) moving into Recovery Stage 2 (Reduced Frequency, months 2–4). Frequency changes before severity, and severity before structure. Expecting that order in reverse is the commonest reason people abandon the work at the Partial Improvement Plateau around weeks three to six, where improvement appears and then flares continue anyway. That plateau is not failure. It is the signal that Phase L has finished its work and Phase I should begin.
Not every patient responds equally. Disease duration, degree of organ involvement, and remaining biological repair capacity all influence outcomes, and patients with very advanced structural changes (severe fibrotic HS) may not achieve full remission. A personalised evaluation is the only way to assess your specific response potential.
One thing worth doing first
Track three cycles: day of onset, site, severity, day of resolution, all recorded against day one of bleeding. A three-cycle diary is the single most useful document you can bring to an evaluation, because it converts "I think it's hormonal" into a driver profile.
Evaluation is by video or WhatsApp consultation. Personalised formulations are dispatched by courier and taken at home.
